U.S. Thyroid Cancer Diagnostics Market Size, Share & Trends Analysis Report By Cancer (Papillary Carcinoma, Follicular Carcinoma), By Technique (Imaging, Biopsy), By End Use, By Region, And Segment Forecasts, 2025 - 2033

Market Size & Trends

The U.S. thyroid cancer diagnostics market size was estimated at USD 1.02 billion in 2024 and is projected to reach USD 1.48 billion by 2033, growing at a CAGR of around 4.30% from 2025 to 2033. Thyroid cancer diagnostics in the U.S. are rapidly evolving, with 2025 estimates projecting 44,020 new cases and 2,290 deaths. The disease is more common in women, often diagnosed at a younger age, and less prevalent among Black populations. While incidence rose for decades due to overdiagnosis from imaging, stricter criteria have reduced rates by 2% annually since 2014. Advances in genomics, AI-driven imaging, and molecular testing now enable precision medicine, reduce overtreatment, and improve outcomes for aggressive subtypes.

Thyroid cancer diagnostics in the United States are evolving rapidly, shaped by changing incidence trends, risk factors, and advances in molecular tools. In 2025, the American Cancer Society projects about 44,020 new cases (12,670 in men and 31,350 in women) and 2,290 deaths, with diagnosis typically occurring at a younger age (average 51 years). The disease is nearly three times more common in women than in men and is about 40-50% less common among Black populations compared to other groups. Over the past four decades, incidence rose dramatically, largely due to widespread use of sensitive imaging tests that detected small, localized tumors with excellent survival rates-many of which represented overdiagnosis. Since 2014, stricter diagnostic criteria have helped reduce overdiagnosis, leading to a 2% annual decline in incidence, while mortality has remained stable since 2009.

Key etiological insights have emerged alongside these trends. Historically, childhood radiation exposure was the only modifiable risk factor; however, obesity has now been recognized as a major contributor, though its biological mechanisms are not fully understood. Research is also examining the role of endocrine-disrupting chemicals and thyroid dysfunction in disease development. Importantly, genetic and molecular profiling has identified critical mutations-such as BRAFV600E, RAS, RET, and NTRK-that are both prognostic and predictive, offering targets for precision therapies. These discoveries have not only improved disease understanding but have also reshaped diagnostics by integrating molecular assays and next-generation sequencing into biopsy evaluation, allowing better differentiation between benign and malignant nodules.

U.S. Thyroid Cancer Diagnostics Market Report Segmentation

This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. thyroid cancer diagnostics market report based on cancer, technique, end use, and region:

• Cancer Outlook (Revenue, USD Million, 2021 - 2033)
• Papillary carcinoma
• Follicular carcinoma
• Others
• Technique Outlook (Revenue, USD Million, 2021 - 2033)
• Blood Test
• Imaging
• Biopsy
• Others
• End Use Indication Outlook (Revenue, USD Million, 2021 - 2033)
• Hospital Laboratories
• Cancer Diagnostic Centers
• Research Institutes
• Others

Please note The report will be delivered in 2-3 business days upon order notification. Show more